BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36139570)

  • 1. Prognostic Potential of the Baseline Pan-Immune-Inflammation Value and Neutrophil/Lymphocyte Ratio in Stage I to III Melanoma Patients.
    Gambichler T; Stang A; Mansour R; Scheel CH; Nick C; Abu Rached N; Becker JC; Susok L
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line Therapy.
    Fucà G; Beninato T; Bini M; Mazzeo L; Di Guardo L; Cimminiello C; Randon G; Apollonio G; Bisogno I; Del Vecchio M; Lauria Pantano C; Di Nicola M; de Braud F; Del Vecchio M
    Target Oncol; 2021 Jul; 16(4):529-536. PubMed ID: 34076798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis.
    Provenzano L; Lobefaro R; Ligorio F; Zattarin E; Zambelli L; Sposetti C; Presti D; Montelatici G; Ficchì A; Martinetti A; Arata A; Del Vecchio M; Lauria Pantano C; Formisano B; Bianchi GV; Capri G; de Braud F; Vernieri C; Fucà G
    Ther Adv Med Oncol; 2023; 15():17588359231165978. PubMed ID: 37063779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pan-immune-inflammation value independently predicts disease recurrence in patients with Merkel cell carcinoma.
    Gambichler T; Said S; Abu Rached N; Scheel CH; Susok L; Stranzenbach R; Becker JC
    J Cancer Res Clin Oncol; 2022 Nov; 148(11):3183-3189. PubMed ID: 35098389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pan-immune-inflammation value and systemic immune-inflammation index in advanced melanoma patients under immunotherapy.
    Susok L; Said S; Reinert D; Mansour R; Scheel CH; Becker JC; Gambichler T
    J Cancer Res Clin Oncol; 2022 Nov; 148(11):3103-3108. PubMed ID: 35006344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The preoperative pan-immune-inflammation value is a novel prognostic predictor for with stage I-III colorectal cancer patients undergoing surgery.
    Sato S; Shimizu T; Ishizuka M; Suda K; Shibuya N; Hachiya H; Iso Y; Takagi K; Aoki T; Kubota K
    Surg Today; 2022 Aug; 52(8):1160-1169. PubMed ID: 35015151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pan‑immune‑inflammation value as a novel prognostic biomarker in nasopharyngeal carcinoma.
    Su Z; Tang J; He Y; Zeng WH; Yu Q; Cao XL; Zou GR
    Oncol Lett; 2024 Jun; 27(6):252. PubMed ID: 38646495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.
    Capone M; Giannarelli D; Mallardo D; Madonna G; Festino L; Grimaldi AM; Vanella V; Simeone E; Paone M; Palmieri G; Cavalcanti E; Caracò C; Ascierto PA
    J Immunother Cancer; 2018 Jul; 6(1):74. PubMed ID: 30012216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials.
    Fucà G; Guarini V; Antoniotti C; Morano F; Moretto R; Corallo S; Marmorino F; Lonardi S; Rimassa L; Sartore-Bianchi A; Borelli B; Tampellini M; Bustreo S; Claravezza M; Boccaccino A; Murialdo R; Zaniboni A; Tomasello G; Loupakis F; Adamo V; Tonini G; Cortesi E; de Braud F; Cremolini C; Pietrantonio F
    Br J Cancer; 2020 Aug; 123(3):403-409. PubMed ID: 32424148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma.
    Zaragoza J; Caille A; Beneton N; Bens G; Christiann F; Maillard H; Machet L
    Br J Dermatol; 2016 Jan; 174(1):146-51. PubMed ID: 26343230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early inflammatory biomarkers and melanoma survival.
    Fortes C; Mastroeni S; Zappalà AR; Passarelli F; Ricci F; Abeni D; Michelozzi P
    Int J Dermatol; 2023 Jun; 62(6):752-758. PubMed ID: 36872079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors.
    Corti F; Lonardi S; Intini R; Salati M; Fenocchio E; Belli C; Borelli B; Brambilla M; Prete AA; Quarà V; Antista M; Fassan M; Morano F; Spallanzani A; Ambrosini M; Curigliano G; de Braud F; Zagonel V; Fucà G; Pietrantonio F
    Eur J Cancer; 2021 Jun; 150():155-167. PubMed ID: 33901794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
    Song A; Eo W; Lee S
    World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic value of neutrophil-lymphocyte ratio is superior to derived neutrophil-lymphocyte ratio in advanced gastric cancer treated with preoperative chemotherapy and sequential R0 resection: a 5-year follow-up.
    Jin H; Sun J; Zhu K; Liu X; Zhang Q; Shen Q; Gao Y; Yu J
    Onco Targets Ther; 2017; 10():2655-2664. PubMed ID: 28579803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios as Biomarkers of Survival in Cutaneous Melanoma: A Multicenter Cohort Study.
    Wade RG; Robinson AV; Lo MCI; Keeble C; Marples M; Dewar DJ; Moncrieff MDS; Peach H
    Ann Surg Oncol; 2018 Oct; 25(11):3341-3349. PubMed ID: 30066226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relation of baseline neutrophil-to-lymphocyte ratio to survival and toxicity in head and neck cancer patients treated with (chemo-) radiation.
    Bojaxhiu B; Templeton AJ; Elicin O; Shelan M; Zaugg K; Walser M; Giger R; Aebersold DM; Dal Pra A
    Radiat Oncol; 2018 Nov; 13(1):216. PubMed ID: 30400969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Relationship between preoperative inflammatory indexes and prognosis of patients with rectal cancer and establishment of prognostic nomogram prediction model].
    Zhang L; Shi FY; Qin Q; Liu GX; Zhang HW; Yan J; Tan M; Wang LZ; Xue D; Hu CH; Zhang Z; She JJ
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):402-409. PubMed ID: 35615796
    [No Abstract]   [Full Text] [Related]  

  • 19. Pretreatment Neutrophil-to-Lymphocyte Ratio: A Prognostic Biomarker of Survival in Patients With Epithelial Ovarian Cancer.
    John-Olabode SO; Okunade KS; Olorunfemi G; Soibi-Harry A; Rimi G; Osunwusi B; Okunowo A; Amaeshi L; Anorlu R
    Cureus; 2021 Jul; 13(7):e16429. PubMed ID: 34422466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of outcomes in inflammatory breast cancer.
    Al Jarroudi O; El Bairi K; Abda N; Zaimi A; Jaouani L; Chibani H; Afqir S
    Biomark Med; 2021 Oct; 15(14):1289-1298. PubMed ID: 34486882
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.